(Q45121503)

9 December 2017

Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin (English)

1 reference

9 December 2017

1 reference

1 reference

Benjamin C Gebhart

1

1 reference

9 December 2017

Brian C Barker

series ordinal

2

1 reference

9 December 2017

Boaz A Markewitz

series ordinal

3

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

9 December 2017

1 reference

9 December 2017

27

1 reference

9 December 2017

3

1 reference

9 December 2017

476-479

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003.

9 December 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Community-acquired methicillin-resistant Staphylococcus aureus: a meta-analysis of prevalence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Current use for old antibacterial agents: polymyxins, rifampin, and aminoglycosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Linezolid and rifampin: Drug interaction contrary to expectations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

Transporters and drug therapy: implications for drug disposition and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.27.3.476

21 January 2018

Identifiers

DOI

10.1592/PHCO.27.3.476

1 reference

9 December 2017

1 reference